3-MeO-PCP

3-MeO-PCP (3-methoxyphencyclidine) is a synthetic dissociative of the arylcyclohexylamine class, a methoxylated analog of phencyclidine (PCP). It is among the most widely discussed and actively used research chemical dissociatives, with one of the largest community footprints of any novel dissociative. 3-MeO-PCP is distinguished from most other arylcyclohexylamines by a pronounced stimulant and euphoric character — at lower doses it functions more like a stimulant-dissociative hybrid than a sedating dissociative — and by an unusually high risk of dose-dependent mania, grandiosity, and psychosis that has generated extensive community safety discussion.

The community contains rich and detailed experience data for 3-MeO-PCP across multiple risk domains. Warning threads about potentially contaminated batches, first-person accounts of manic episodes, AMAs from daily microdosers (including one documenting 7+ months of daily use for ADHD and depression), and reports of severe experiences following high-dose insufflation all appear in community archives. Recurrent themes include: the steep dose-response curve where modest dose increases dramatically shift effects from functional to dysregulating; the insidious quality of mania in which users feel exceptionally capable and clear-headed while becoming behaviorally disinhibited; the unusual stimulant character that makes it appealing for exercise or social activities at low doses; and the risks of combining with Suboxone or other medications.

Despite these risks, 3-MeO-PCP has maintained consistent interest because of its distinctive pharmacological character: for users who can navigate its narrow therapeutic window, it reportedly offers a uniquely euphoric, cognitively stimulating dissociative experience unlike ketamine or classical arylcyclohexylamines. The harm reduction community broadly classifies it as one of the higher-risk common dissociatives.